Molecular pathology and clinical characteristics of oligodendroglial neoplasms

Authors:
  • DPDaniel G. Du Plessis
    Daniel G. Du Plessis
  • KJKathy A. Joyce
    Kathy A. Joyce
  • AGAbigail Gee
    Abigail Gee
  • BHBrian Haylock
    Brian Haylock
  • DHDavid Husband
    David Husband
  • TSTrevor Smith
    Trevor Smith
  • JBJohn Broome
    John Broome
  • PWPeter C. Warnke
    Peter C. Warnke
Publisher website
Google Scholar
Abstract
To evaluate the role of molecular genetics in the routine clinic, we investigated allelic imbalance at 1p36, 19q13, 17p13, 10p12‐15, and 10q22‐26 and p53 mutation in 100 oligodendroglial neoplasms diagnosed at a single treatment center between 2000 and 2003. The ‐1p/‐19q genotype, seen in 64, 34, 77, and 30% of OII, OAII, OIII, and OAIII respectively, was inversely related to p53 mutation and 17p13 loss. Genotype was unrelated to tumor location and could not distinguish high‐grade tumors that presented de novo from those that progressed from a previous lower grade malignancy. Presentation with seizures was more common in cases with the ‐1p/‐19q genotype, and these remained stable for longer before treatment. In longitudinal samples, 74% retained their initial histological differentiation, whereas 29% showed new genetic alterations, the ‐1p/‐19q genotype being acquired in three cases. Loss of 1p36 and 19q13, 17p13, chromosome 10, and p53 mutation were significantly associated with survival from presentation in Kaplan–Meier analysis (p < 0.01), and loss of 1p36 and 19q13 and loss of 17p13 retained significance in multivariate analysis. In this recently diagnosed unselected series, clinical differences in tumors with and without the ‐1p/‐19q genotype support a genetic approach to aid diagnosis and prognostication for oligodendroglial neoplasms. Ann Neurol 2005;57:855–865

This publication has 39 references indexed in Scilit: